GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Late-stage data unveiled on Thursday showed GSK's respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults.

GSK says key trial data shows its RSV vaccine is 'truly exceptional'

Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.

GSK's (GSK) Boostrix Gets FDA Nod for Pertussis in Newborns

It is the first shot the FDA has approved for use during pregnancy to prevent a disease in young infants by immunizing their mothers.

FDA approves first vaccine to prevent whooping cough in newborns by giving shot to mother during pregnancy

BioNTech SE

Tenet Healthcare

These stocks could attract both value and growth investors.

3 Dirt-Cheap Stocks That Could Soar 48% to 68%, According to Wall Street

GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.

GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal

GSK's price might have underwhelmed recently, but it's picking up now, calling for a closer look at it after a demerger with its consumer healthcare division last quarter. It's largely well placed to face macroeconomic pressures of slow growth, high inflation, and rising interest rates with strong margins and muted debt.

GSK: Some Upside Likely

GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up for the lower sales of established drugs due to generic erosion.

GSK's Key Drugs to Drive Sales in a Sluggish Second Half

Best Buy

Barclays

Ford Motor Company

Intel

Iron Mountain

Altria

With recent stock market weakness, look for long-term dividend stocks to buy. After failing to hold a rally that began in June 2022, the S&P 500 erased more than it gained by Sept.

This Is the Best Time to Buy These 7 Long-Term Dividend Stocks

Glaxo (GSK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Here is What to Know Beyond Why GSK PLC Sponsored ADR (GSK) is a Trending Stock

The rise in GSK PLC (LSE:GSK, NYSE:GSK) shares on the reporting of a finance chief was probably more to do with the slide in sterling, than the market's excitement about the creation of an all-female top team, said Barclays. Following the drug maker announcing that Julie Brown is being poached from Burberry to take the role of chief financial officer as Iain Mackay retires, the general reception to the news today has been positive, the bank said.

GSK board appointment is positive says broker but focus is on weak GBP, Zantac legals

AstraZeneca

British American Tobacco

Ferguson Enterprises Inc

Haleon PLC

As the pound crashed following Kwasi Kwarteng's quasi-infamous ‘mini' budget, many crafty currency speculators made a quick fortune, while savvy stock market investors are still mulling which companies are likely to benefit most. Sterling has never been so weak, which in theory should make products sold by UK exporters potentially very much more attractive.

AstraZeneca, BAT, Ferguson, 4imprint and other exporters get double-benefit from sterling crash

GSK PLC (LSE:GSK, NYSE:GSK) poached Burberry Group PLC (LSE:BRBY)'s chief financial officer (CFO) Julie Brown to complete a rare but all-female executive leadership team. Brown will replace Iain Mackay, who has been finance chief at the FTSE-100 pharmaceuticals giant since 2019.

GSK poaches Burberry CFO to complete rare all-female executive leadership team

GSK named luxury fashion brand Burberry's Julie Brown as its first ever female chief financial officer on Monday to succeed Iain Mackay, at a time when the British drugmaker is sharpening focus on its core business.

GSK picks Burberry's Brown as first female CFO

British drugmaker GSK plc , has poached Burberry Group's finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday.

GSK poaches Burberry CFO Julie Brown to create all-female top team - Sky News

Dollar General

Dollar Tree

Fortinet

Eli Lilly

Cheniere Energy

McDonald's

Many commentators, analysts, and economists are convinced that the U.S. will enter a recession next year. Given the strength of the labor market and of corporate balance sheets, along with the onshoring phenomenon and the many jobs that the energy transition is creating, I have my doubts as to whether a recession is on the way.

7 Stocks to Buy That Can Soar in Good Times or in Bad

Spero Therapeutics

Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimental antibiotic for complicated urinary tract infections. Spero's therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year.

Spero's stock jumps 188% after GSK licenses experimental antibiotic

GSK PLC (LSE:GSK, NYSE:GSK) has inked a licensing deal with a Cambridge, Massachusetts, biotech that will give it access to an oral antibiotic for complicated urinary tract infections. The UK group is paying Spero Therapeutics Inc an initial US$66mln to licence the latter's tebipenem pivoxil hydrobromide, which is about to enter phase III clinical trials.

GSK to shell out an initial US$75mln to gain rights to a next-generation antibiotic

Is Trending Stock GSK PLC Sponsored ADR (GSK) a Buy Now?

Pfizer

Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.

Haleon rejects Zantac indemnification requests from GSK, Pfizer

GSK PLC (LSE:GSK, NYSE:GSK) has been upgraded by Credit Suisse on the assumption that its potential liability for Zantac lawsuits will be much smaller than the US$12bn that has been wiped from its market cap in recent weeks. The Swiss bank swapped its ‘sell' rating for a ‘hold' but trimmed the share price target to 1,430p from 1,630p to reflect a US$5bn base-case of liability costs from Zantac.

GSK 'sell' rating removed as Zantac liabilities expected to be US$5bn

Glaxo (GSK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Most-Watched Stock GSK PLC Sponsored ADR (GSK) Worth Betting on Now?

GSK plc (NYSE:GSK ) Citi's 17th Annual BioPharma Conference September 7, 2022 1:50 PM ET Company Participants Roger Connor - President, Global Vaccines & Global Health Phil Dormitzer - Senior Vice President, Head of Vaccines R&D Conference Call Participants Andrew Baum - Citigroup Andrew Baum Terrific. Well, welcome back.

GSK plc (GSK) Citi's 17th Annual BioPharma Conference Earnings Call Transcript

GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.

GSK's NDA for Daprodustat to be Reviewed by an FDA Panel

Viatris

Verizon

With all the recent market volatility, there is no shortage of stocks that are looking seemingly cheaper when compared to the closing months of 2021. First up, I'm thinking about adding to the recent spin-off Viatris Inc.

September 2022 Stock Considerations

Two major investment banks cut their target prices for GSK PLC (LSE:GSK, NYSE:GSK) as analysts drilled down into the potential fallout from the Zantac litigation and saw the potential for total liabilities for the companies involved of over US$50bn. Morgan Stanley (NYSE:MS) cut its price target to 1,550p from 1,860p, while Deutsche Bank cut to 1,500p from 1,750p.0 Even though the first of the legal cases against companies that sold the heartburn drug was dropped last month, Deutsche analyst Emmanuel Papadakis said a detailed review of the Zantac litigation led the bank to believe GSK and Sanofi are likely to "lose the scientific argument" and consequently are likely to incur liabilities.

GSK targets further cut by investment banks over potential Zantac legal risks

News for GlaxoSmithKline Stock (GSK)